News | March 05, 2024
Biocon Biologics secures Canada market entry date for YESAFILI
This agreement paves the way for the introduction of YESAFILI into the Canadian market
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Total transaction value of the divestment is Rs. 3,660 million
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra
Subscribe To Our Newsletter & Stay Updated
